Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

<p>Abstract</p> <p>Background</p> <p>Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate and disability progression, and improves health-related quality of life (HRQoL), in patients with relapsing-remitting multiple scleros...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephenson Judith J, Kern David M, Agarwal Sonalee S, Zeidman Ruth, Rajagopalan Krithika, Kamat Siddhesh A, Foley John
Format: Artigo
Language:Inglês
Published: BMC 2012-12-01
Series:Health and Quality of Life Outcomes
Subjects:
Cognitive function
Health-related quality of life
Multiple sclerosis
Natalizumab
Patient-reported outcomes
Online Access:http://www.hqlo.com/content/10/1/155
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items